The U.S. FDA late Friday approved BridgeBio Pharma’s (NASDAQ:BBIO) lead asset Attruby for the rare heart disorder ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

Equities researchers at Cantor Fitzgerald decreased their FY2024 earnings estimates for BridgeBio Pharma in a report released ...

On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been assigned an average recommendation of “Moderate ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a commercial-stage biopharmaceutical company focused on developing transformative medicines for patients with genetic diseases and cancers. Its primary ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by Scotiabank from $44.00 to $45.00 in a research note published on Friday,Benzinga reports. The brokerage currently has a ...

One thing we could say about the analysts on BridgeBio Pharma, Inc. ( NASDAQ:BBIO) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...

Equities research analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of BridgeBio ...

PALO ALTO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new ...

In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other biotech stocks. Biotechnology stocks are among the most volatile in the market ...